[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cancer Hospital of Guangxi Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100493643","sintilimab-in-combination-with-chemoradiotherapy-in-high-risk-locoregionally-advanced-nasopharyngeal-carcinoma-100493643",false,"NCT05707819","Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","Sintilimab (PD-1 Antibody) in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma: a Single-arm, Multicentre, Phase 2 Trial","Inclusion Criteria:\n\n1. Patients with histologically confirmed Non-keratinizing nasopharyngeal carcinoma.\n2. Tumor staged as III-IVA (AJCC 8th, T3-4N2-3M0).\n3. Eastern Cooperative Oncology Group performance status ≤1.\n4. Adequate marrow function: neutrocyte count≥1.5×10e9\u002FL, hemoglobin ≥90g\u002FL and platelet count ≥100×10e9\u002FL.\n5. Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN.\n6. Adequate renal function: creatinine clearance rate ≥ 60 ml\u002Fmin (Cockcroft-Gault formula).\n7. Patients must be informed of the investigational nature of this study and give written informed consent.\n8. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug.\n\nExclusion Criteria:\n\n* 1.Age \\> 70 or \\\u003C 18. 2.Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA \\>1×10e3 copies\u002Fml or 200IU\u002Fml 3.Hepatitis C virus (HCV) antibody positive 4.Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment.\n\n  5.Has a known history of interstitial lung disease. 6.Has any condition that required systemic corticosteroid (equivalent to prednisone \\>10mg\u002Fd) or other immunosuppressive therapy within 28 days before informed consent. Patients received systemic corticosteroid equivalent to prednisone ≤10mg\u002Fd, inhale or topical corticosteroid will be allowed.\n\n  7.Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future.\n\n  8.Is pregnant or breastfeeding. 9.Has a history of other malignancies except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer.\n\n  10.Has known allergy to large molecule protein products or any compound of sintilimab.\n\n  11.Has a known history of human immunodeficiency virus (HIV) infection. 12.Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic\u002Fsocial factors, deemed by the investigator to be likely to interfere with a","ALL","18 Years","70 Years",{"count":20,"type":21},43,"ESTIMATED","OBSERVATIONAL","The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.",[25,26],"Nasopharyngeal Carcinoma","Sintilimab",[25,26,28],"high risk","RECRUITING","2023-01-29",{"date":32,"type":33},"2023-02-01","ACTUAL",{"date":35,"type":33},"2022-07-30",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Cancer Hospital of Guangxi Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100391429","phase-3-toripalimab-for-local-regional-recurrent-nasopharyngeal-carcinoma-100391429","NCT04376866","Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma","Toripalimab in Combination With Concurrent Chemoradiotherapy for Local-regional Recurrent Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recurrent tumor\n2. staged as rT3-4N0-1M0或rT1-4N2-3M0 （according to the 8th AJCC edition）\n3. Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1\n4. Neutrophil ≥ 1.5×109 \u002FL and PLT ≥4×109 \u002FL and HGB ≥90 g\u002FL\n5. With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN)\n6. With normal renal function test ( creatinine clearance ≥60 ml\u002Fmin)\n7. sign an \"informed consent form\n8. Male and no pregnant female\n\nExclusion Criteria:\n\n1. Age older than 65, or younger than 18 years old\n2. Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥200IU\u002Fml, or 1000cps\u002Fml.\n3. Patients with positive HCV antibody.\n4. Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those only need hormone replacement therapy, and skin disease (leukoderma, psoriasis, alopecia et al) who don't need systemic therapy can recruit.\n5. History of interstitial lung disease\n6. Equivalent dose more than prednisone 10mg\u002Fd or other immunosuppressive treatments within 28 days prior to signing the informed consent.\n7. Receive or will receive live vaccine within 30 days prior to signing the informed consent.\n8. Women of child-bearing potential who are pregnant or breastfeeding.\n9. Suffered from malignant tumors, except the carcinoma in situ, papillary thyroid carcinoma, or skin cancer (non- melanoma) within five years.\n10. Hypersensitivity to macromolecular protein, or to any component of triplezumab.\n11. HIV positive.\n12. Severe, uncontrolled medical conditions and infections.\n13. Other diseases which may influence the safety or compliance of the clinical trial, such as heart failure with symptom, unstable angina, myocardial infarction, active infections those need systemic therapy, mental illness, or their family and society factors.","65 Years",{"count":51,"type":21},204,"INTERVENTIONAL",[54],"PHASE3","This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.",[57],"Recurrent Nasopharyngeal Carcinoma",[57,59,60],"Toripalimab","Concurrent chemoradiotherapy","2021-07-18",{"date":63,"type":33},"2021-07-20",{"date":65,"type":33},"2020-06-28",{"date":67,"type":21},"2028-04",{"name":39,"class":40},""]